Imaginostics develops non-invasive quantitative imaging technology compatible with existing MRI scanners to assess vascular health and disease. Their solutions provide early diagnostics and drug efficacy evaluation, enhancing patient care through detailed visualization of structural and functional abnormalities.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing vascular health often involve invasive procedures or lack the sensitivity to detect subtle structural and functional abnormalities in early stages of disease. This can lead to delayed diagnoses and limit the ability to evaluate the effectiveness of new therapies.
Solution
Imaginostics develops non-invasive quantitative imaging technology that integrates with existing MRI scanners to provide detailed assessments of vascular health and disease. Their technology uses advanced quantitative imaging biomarkers to visualize the vasculature and identify structural and functional abnormalities. The resulting data can be used for early diagnostics, patient stratification, and drug efficacy evaluation in clinical trials. By providing a comprehensive view of vascular health, Imaginostics aims to improve patient care through earlier detection and more informed treatment decisions.
Target Audience
The primary audience includes clinicians, researchers, and pharmaceutical companies focused on neuroscience, cancer, and cardiology, particularly those interested in early diagnostics, precision medicine, and drug development.
Features
- Non-invasive quantitative imaging biomarkers for assessing vascular structure and function
- Compatible with existing MRI scanners and hardware
- Full-body health assessment of vascular abnormalities
- Biomarker solutions for neurologic disease, neurofunctional pharmacokinetics, cardiac, kidney, and cancer applications
- Visualization of the vasculature to assay health and disease
- Tools to stratify patient populations